News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
ICICI Direct’s analysis of Cipla’s Q3FY22 results
This is the company’s first partnership arrangement in China
The stability is led by healthy demand in the domestic and emerging markets
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Nelarabine is in a class of medications called antimetabolites
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Subscribe To Our Newsletter & Stay Updated
